Orchestra BioMed Holdings (OBIO) Insider & Congress Trades

Smart money at a glance

Filings to Nov 13, 2026

Net buying: insiders sold $256K and bought $6.1M on the open market in 90 days (SEC Form 4). Congress: no trades disclosed in 180 days.

Company insidersForm 4, 90 days: +$5.8M net
CongressSTOCK Act, 180 days: None
Big funds13F, quarter ended Jun 30, 2026: 1 added, 0 cut
Federal contractsUSAspending.gov, 12 months: No awards

Analysts

What do analysts expect?

Analyst target and ratings are on paid plans

Unlock the full results

Questions about OBIO filings

Are insiders buying or selling Orchestra BioMed Holdings Inc. (OBIO) stock?

Net buying: insiders sold $256K and bought $6.1M of OBIO stock on the open market in the 90 days to Nov 13, 2026, according to SEC Form 4 filings. $256K of the sales were made under pre-set Rule 10b5-1 trading plans. The largest was Wong, Roderick (10% owner), who bought $6M. The latest filing was on Nov 12, 2026.

Which members of Congress have traded OBIO recently?

None. No member of Congress disclosed a OBIO trade with a trade date in the last 180 days, according to House and Senate STOCK Act filings.

How current is this OBIO smart-money data?

This summary uses filings available on Nov 13, 2026. Insiders must report trades to the SEC within 2 business days, members of Congress have up to 45 days to disclose a trade, and funds file 13F holdings up to 45 days after each quarter ends, so the latest moves may not be public yet.

13F: filed up to 45 days late.

Smart money on OBIO

Lean long2 sources:
- Insiders
- Funds

Top traders
No tracked positions at the last update
Insiders
- LP Rtw Investments, bought $6M, open market, filed Nov 12
Lean long · thin1 buy · $6M
Form 4 filings, open market.
Congress
No recent politician filings found
Funds
- BlackRock, added +$8.1M, holdings at Jun 30
Lean long · thin1 added · 0 trimmed
Quarter-end 13F holdings changes, not live trades. A trim is not a short.
Influencers
No recent posts found

Each bar is 100% of that source’s money. The notch marks an even split.

Lean is the direction of the latest moves. Descriptive, not advice.

Questions about OBIO filings

Are insiders buying or selling Orchestra BioMed Holdings Inc. (OBIO) stock?

Which members of Congress have traded OBIO recently?

None. No member of Congress disclosed a OBIO trade with a trade date in the last 180 days, according to House and Senate STOCK Act filings.

How current is this OBIO smart-money data?

Funds

What funds are doing

1 move · 6 mo

Buys/Adds$8.1M

Buys/Adds (1)

BR
BlackRock
Q2 2026 13F
$8.1M
added
Signals like this: n=13773, 53% finished lower at D15, median -0.4% vs SPY -0.4%

Unlock everything for $29/month

Unlock for $29/month

Reported Nov 10, 2026

Earnings came in 2.6% below what analysts expected.

Documents

Quarterly report10-Q Annual report10-K Every filing

Last report

Nov 10, 2026

Period ending

Sep 30, 2026

Earnings per share

-$0.41-2.57% miss

-$0.40 expected

Revenue

$91.0K

SEC filing

EPS: Yahoo Finance

Next report

What the street expects next

Estimates as of Nov 13, 2026

EPS expected

-$0.41

-$0.49 to -$0.38

Revenue expected

$106.8K

6 analysts

Last 30 days

1up1down

Split both ways

Previous reports

Quarter / reported	Earnings per share	Beat or miss	Revenue / income	Revenue vs last year
Sep 30, 2026Reported Nov 10, 2026	-$0.41est. -$0.40	-2.57%miss	$91.0KSEC filing	-89.4%from $861.0K
Jun 30, 2026Reported Aug 10, 2026	-$0.38est. -$0.35	-8.57%miss	$88.0KSEC filing	-89.5%from $836.0K
Mar 31, 2026Reported May 12, 2026	-$0.33est. -$0.44	+25.55%beat	$110.0KSEC filing	-87.3%from $868.0K
Dec 31, 2025Reported Mar 12, 2026	$0.26est. -$0.38	+$0.64beat	$30.9MAlpha Vantage	+12120.2%from $253.0K
Sep 30, 2025Reported Nov 10, 2025	-$0.40est. -$0.43	+6.72%beat	$861.0KSEC filing	-12.8%from $987.0K
Jun 30, 2025Reported Aug 12, 2025	-$0.50est. -$0.51	+1.96%beat	$836.0KSEC filing	+7.5%from $778.0K
Mar 31, 2025Reported Apr 2, 2025	-$0.49est. -$0.48	-2.08%miss	$868.0KSEC filing	+40.0%from $620.0K
Dec 31, 2024Reported Mar 26, 2025	-$0.42est. -$0.45	+6.67%beat	$253.0KAlpha Vantage	-3.4%from $262.0K

Earnings per share comes from Yahoo Finance where available, then Alpha Vantage or the company release. Revenue comes from company releases, SEC filings, Alpha Vantage or Yahoo Finance. A beat or miss needs an analyst estimate on the same basis as the reported figure, so quarters without one show none. Non-USD amounts carry their currency code.

Open: $5.99
High: $6.18
Low: $5.70
Prev close: $6.01
52-wk high: $6.50
52-wk low: $3.46
Mkt cap: $484.0M
ROE: -182.3%
Beta: 0.55
P/S: 15.5x
P/B: 62.2x
Profit margin: -185.3%
Op margin: -195.4%

Dec 2025 to Sep 2026

What it sold, what it cost, what was left.

RevenueProfit

Dec 2025Mar 2026Jun 2026Sep 2026

Income statement, 4 periods, all values in US dollars
USD	Dec 2025	Mar 2026	Jun 2026	Sep 2026
What came in
RevenueTotal revenue	$30.9M	$110.0K	$88.0K	$91.0K
Cost of what it soldCost of revenue	$51.0K	$92.0K	$25.0K	$28.0K
Gross profit	$30.9M	$18.0K	$63.0K	$63.0K
What it spent
Research and development	$16.8M	$15.8M	$16.6M	$17.7M
Sales and adminSelling, general and administrative	$7.3M	$6.4M	$5.8M	$5.6M
Total operating expenses	$24.1M	$22.1M	$22.4M	$23.4M
What was left
Operating profitOperating income	$6.8M	-$22.1M	-$22.4M	-$23.3M
Interest on debtInterest expense	$763.0K	$821.0K	$1.8M	$2.5M
Profit before tax	$6.2M	-$20.7M	-$23.8M	-$19.6M
Net profitNet income	$6.2M	-$20.7M	-$23.8M	-$19.6M
EBITDAEarnings before interest, tax, depreciation, amortisation	$7.1M	-$19.8M	-$23.7M	-$23.3M

Technicals

Price structure

This stock is in a strong uptrend.

Trend

Strong uptrend

100 / 100

RSI 14

61balanced

20D volatility

61%annualized

52-week range

$6.15

$3.46$6.50

20D support

$5.10recent floor

20D resistance

$6.34recent ceiling

Returns

5D +9.4%20D +7.1%60D +10.8%

Price vs moving averages

SMA20 +6.7%SMA50 +5.8%SMA200 +33.4%

Volume pace

1.53xvs prior 20D

Quarter / reported

Earnings per share

Beat or miss

Revenue / income

Revenue vs last year

Sep 30, 2026Nov 10, 2026

-$0.41est. -$0.40

-2.57%

$91.0KSEC filing

-89.4%from $861.0K

Jun 30, 2026Aug 10, 2026

-$0.38est. -$0.35

-8.57%

$88.0KSEC filing

-89.5%from $836.0K

Mar 31, 2026May 12, 2026

-$0.33est. -$0.44

+25.55%

$110.0KSEC filing

-87.3%from $868.0K

Dec 31, 2025Mar 12, 2026

$0.26est. -$0.38

+$0.64

$30.9MAlpha Vantage

+12120.2%from $253.0K

Sep 30, 2025Nov 10, 2025

-$0.40est. -$0.43

+6.72%

$861.0KSEC filing

-12.8%from $987.0K

Jun 30, 2025Aug 12, 2025

-$0.50est. -$0.51

+1.96%

$836.0KSEC filing

+7.5%from $778.0K

Mar 31, 2025Apr 2, 2025

-$0.49est. -$0.48

-2.08%

$868.0KSEC filing

+40.0%from $620.0K

Dec 31, 2024Mar 26, 2025

-$0.42est. -$0.45

+6.67%

$253.0KAlpha Vantage

-3.4%from $262.0K

Income statement, 4 periods, all values in US dollars
USD	Dec 2025	Mar 2026	Jun 2026	Sep 2026
What came in
RevenueTotal revenue	$30.9M	$110.0K	$88.0K	$91.0K
Cost of what it soldCost of revenue	$51.0K	$92.0K	$25.0K	$28.0K
Gross profit	$30.9M	$18.0K	$63.0K	$63.0K
What it spent
Research and development	$16.8M	$15.8M	$16.6M	$17.7M
Sales and adminSelling, general and administrative	$7.3M	$6.4M	$5.8M	$5.6M
Total operating expenses	$24.1M	$22.1M	$22.4M	$23.4M
What was left
Operating profitOperating income	$6.8M	-$22.1M	-$22.4M	-$23.3M
Interest on debtInterest expense	$763.0K	$821.0K	$1.8M	$2.5M
Profit before tax	$6.2M	-$20.7M	-$23.8M	-$19.6M
Net profitNet income	$6.2M	-$20.7M	-$23.8M	-$19.6M
EBITDAEarnings before interest, tax, depreciation, amortisation	$7.1M	-$19.8M	-$23.7M	-$23.3M

USD

Dec 2025

Mar 2026

Jun 2026

Sep 2026

What came in

RevenueTotal revenue

$30.9M

$110.0K

$88.0K

$91.0K

Cost of what it soldCost of revenue

$51.0K

$92.0K

$25.0K

$28.0K

Gross profit

$30.9M

$18.0K

$63.0K

What it spent

Research and development

$16.8M

$15.8M

$16.6M

$17.7M

Sales and adminSelling, general and administrative

$7.3M

$6.4M

$5.8M

$5.6M

Total operating expenses

$24.1M

$22.1M

$22.4M

$23.4M

What was left

Operating profitOperating income

$6.8M

-$22.1M

-$22.4M

-$23.3M

Interest on debtInterest expense

$763.0K

$821.0K

$1.8M

$2.5M

Profit before tax

$6.2M

-$20.7M

-$23.8M

-$19.6M

Net profitNet income

$6.2M

-$20.7M

-$23.8M

-$19.6M

EBITDAEarnings before interest, tax, depreciation, amortisation

$7.1M

-$19.8M

-$23.7M

-$23.3M

Orchestra BioMed Holdings Inc.

Smart money at a glance

What do analysts expect?

Questions about OBIO filings

Smart money on OBIO

Questions about OBIO filings

What funds are doing

What insiders are doing

How top traders are positioned

Unlock everything for $29/month

Earnings came in 2.6% below what analysts expected.

What the street expects next

Previous reports

What it sold, what it cost, what was left.

Price structure

Ask it in Claude or ChatGPT.

Orchestra BioMed Holdings Inc.

Smart money at a glance

What do analysts expect?

Questions about OBIO filings

Smart money on OBIO

Questions about OBIO filings

What funds are doing

What insiders are doing

How top traders are positioned

Unlock everything for $29/month

Earnings came in 2.6% below what analysts expected.

What the street expects next

Previous reports

What it sold, what it cost, what was left.

Price structure

Ask it in Claude or ChatGPT.

Orchestra BioMed Holdings Inc.

Overview

Questions about OBIO filings

Smart money

Unlock everything for $29/month

Earnings

Previous reports

Financials

Technicals

Ask it in Claude or ChatGPT.

Orchestra BioMed Holdings Inc.

Overview

Questions about OBIO filings

Smart money

Unlock everything for $29/month

Earnings

Previous reports

Financials

Technicals

Ask it in Claude or ChatGPT.